Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Cost-Effectiveness of Treatment for Pediatric Immune Thrombocytopenia

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1425-000

Question

  1. What is the cost-effectiveness of dapsone for pediatric patients with ITP?
  2. What is the cost-effectiveness of rituximab for pediatric patients with ITP?
  3. What is the cost-effectiveness of TPO-R agonists for pediatric patients with ITP?

Key Message

Limited evidence from 1 cost-consequence analysis study showed that eltrombopag was the preferred thrombopoietin receptor agonist over romiplostim (i.e., less expensive and more effective) for treatment of chronic immune thrombocytopenia in pediatric patients. No cost-effectiveness studies of dapsone or rituximab were identified.

Files

Cost-Effectiveness of Treatment for Pediatric Immune Thrombocytopenia View PDF
Last Updated : May 5, 2022